Drug Trial Radar · NCT06362473
Lipid Transport Disorder Italian Genetic Record (LIPIGEN)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15,000
Planned (sponsor's estimate)
Start
Aug 4, 2015
Primary completion
Dec 31, 2036
Study completion Dec 31, 2036
Sponsor
- Lead sponsor
- Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 12, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS). What does the study do? It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures. It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments. It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments. It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes. Who can participate? The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia. More than 50 centres throughout Italy are involved, making the study accessible to many. What does participation entail? Participants will continue with their normal clinical practice. Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures. For some, further evaluations, such as ultrasounds, may be required to better study their condition. The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments.
Conditions
- Familial Hypercholesterolemia
- Genetic Disorder
Interventions
Lipid-lowering treatmentsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lipid profile of patients with genetic dyslipidemiaTime frame: At baseline and through study completion up to 20 years
- Genetic profile of patients with genetic dyslipidemiaTime frame: At baseline evaluation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IRCCS Multimedica
Sesto San Giovanni, Milano, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.